

Treatment Type	🗌 нст 🔲 ст	IST Other
Treatment Date _	// (YY	YY/MM/DD)

### CHRONIC LEUKAEMIAS

### DISEASE

Note: complete this form only if this diagnosis was the indication for the HCT/CT or if it was specifically requested. Consult the manual for further information.

Date of diagnosis: \_ \_ \_ / \_ / \_ \_ (YYYY/MM/DD)

### Classification (WHO 2022):

Chronic myeloid leukaemia (CML)

Chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL) / Richter transformation

Prolymphocytic (PLL) and other chronic leukaemias



Treatment Type	🗌 нст 🗌 ст	🗌 IST	Other

### Treatment Date \_ \_ \_ / \_ / \_ (YYYY/MM/DD)

## **Chronic Myeloid Leukaemias (CML)**

	CHROMO	SOME ANALYSIS	
Describe results of all the analys	is done before HCT/CT trea	tment	
Chromosome analysis done be	efore HCT/CT treatment: is: 🔲 Separate abnormali	ties 🔲 Full karyot	уре
	Copy and fill-in this	section as often as ne	ecessary.
If chromosome analysis was What were the results? Normal Abnormal: number of abu Failed Date of chromosome analy For abnormal results, indicate	normalities present: Y <b>sis:</b> I I (YYY		
t(9;22)	Absent	Present	Not evaluated
Trisomy 8	Absent	Present	☐ Not evaluated
Extra Ph	Absent	Present	Not evaluated
i(17)	Absent	Present	☐ Not evaluated
-7/Del	Absent	Present	Not evaluated
3q26	Absent	Present	Not evaluated
Other; specify:	Absent	Present	
Transcribe the complete karyo	ype:	OR	



Treatment Type	🗌 нст 🗌 ст	IST	Other
Treatment Date _	// (YY	YY/MM/DE	))

### **MOLECULAR MARKER ANALYSIS**

Molecular markers analysi	s done before HCT/CT t	reatment:		
🔲 No				
🗌 Yes				
🔲 Unknown				
	Copy and fill-in this	section as often as necessary.		
If molecular marker analysis	was done:			
Date of molecular marke	r analysis: / /	(YYYY/MM/DD) 🗌 Unknow	'n	
	,		11	
Indicate below whether the n	narkers were absent, pres	sent or not evaluated.		
ASXL1	Absent	Present	Not evaluated	
BCORL1	Absent	Present	Not evaluated	
BCR::ABL1	Absent	Present	Not evaluated	
CBFB-MYH11	Absent	Present	Not evaluated	
EZH2	Absent	Present	Not evaluated	
IDH1	Absent	Present	Not evaluated	
IKZF1	Absent	Present	Not evaluated	
KMT2D	Absent	Present	Not evaluated	
RUNX1	Absent	Present	Not evaluated	
SETD1B	Absent	Present	Not evaluated	
TET2	Absent	Present	Not evaluated	
TP53	Absent	Present:	Not evaluated	
		TP53 mutation type: 🔲 Si	ingle hit	
		M	ulti hit	
			nknown	
Other; specify	Absent	Present		

# **PREVIOUS THERAPIES** (between diagnosis and HCT/CT)

### Previous therapy lines before the HCT/CT/GT:

🗌 No	
Pres:	complete the "Treatment — non-HCT/CT/GT/IST" form
🗌 Unkn	own



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other

Treatment Date \_ \_ \_ / \_ / \_ (YYYY/MM/DD)

# Chronic Lymphocytic Leukaemias (CLL)

DISEASE
---------

Sub-Classification (WHO 2022):	
Chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL	)
Richter transformation:	
Transformed from a previous known CLL: 🔲 No (primary Richter)	
	LL diagnosis: / / (YYYY/MM/DD)
	• /
Type of Richter transformation:	
☐ Other; specify:	
Richter transformation clonally related to CLL: No	
☐ Yes	
	_
CHROMOSOME ANALYSIS	5
Describe results of all the analysis done before HCT/CT treatment	
Chromosome analysis done before HCT/CT treatment:	
$\square$ No	
☐ Yes: <b>Output of analysis:</b> ☐ Separate abnormalities ☐ Full kary	otype
Unknown	
Copy and fill-in this section as often as	s necessary.
If chromosome analysis was done:	
What were the results?	
Normal	
Abnormal: number of abnormalities present:	
☐ Failed	
Date of chromosome analysis: / _ / (YYYY/MM/DD)	Linknown
For abnormal results, indicate below whether the abnormalities were absent	t, present or not evaluated.
Trisomy 12	🔲 Absent 📋 Present 📋 Not evaluated
del(13q14)	Absent Present Not evaluated
del(11q22-23)	Absent Present Not evaluated
del(17p)	🗌 Absent 📋 Present 📋 Not evaluated
Other; specify:	Absent Present
OR Transcribe the complete karyotype:	



Treatment Type	🗌 нст 🔲 ст	IST Other
Treatment Date _	// (YY	YY/MM/DD)

### **MOLECULAR MARKER ANALYSIS**

-	HCT/CT treatment:		
□ No			
Yes			
Unknown			
Сору	and fill-in this section as ofte	en as necessary.	
If molecular marker analysis was done:			
Date of molecular marker analysis: _	//(YYYY/MM/I	DD) 🗌 Unknown	
IGVH mutational status: Absent Present High risk subset? No Yes			
Indicate below whether the markers were a	•		
TP53	Absent, present or not evaluate	d.	Not evaluated
	Absent		
	Absent	Present; 53 mutation type: Sir	
	Absent	Present; 53 mutation type: Sir	ngle hit
	Absent	Present; 53 mutation type: Sir	ngle hit Ilti hit
	Absent	Present; 53 mutation type: Sir	ngle hit Ilti hit
	Absent	Present; 53 mutation type: Sir	ngle hit Ilti hit

# PREVIOUS THERAPIES (between diagnosis and HCT/CT)

Previous therapy lines before the HCT/CT:

No

Yes:

complete the "Treatment — non-HCT/CT/GT/IST" form

Unknown



Treatment Type	🗌 нст 🔲 ст	IST Other
Treatment Date _	// (YY	YY/MM/DD)

# Prolymphocytic (PLL) and Other Chronic Leukaemias

DISEASE	
---------	--

Sub-Classification (WHO 2022): Prolymphocytic and other chronic leukaemias

T-prolymphocytic leukaemia (T-PLL)	
Hairy cell leukaemia	
Splenic B-cell lymphoma/leukaemia with prominent nucleoli (SBLPN)	
Other chronic leukaemia; specify:	

CHROMOSOME ANALYSIS - only applicable for T-PLL			
Describe results of all the analysis done before HCT/CT treatment			
<b>Chromosome analysis done before HCT/CT treatment:</b>			
☐ Yes: output of analysis: ☐ Separate abnormalities ☐ Full karyon ☐ Unknown	type		
Copy and fill-in this section as often as necessary.			
If chromosome analysis was done: What were the results? Normal Abnormal: number of abnormalities present: Failed Date of chromosome analysis:1_1(YYYY/MM/DD) Unknown For abnormal results, indicate below whether the abnormalities were absent, present or not evaluated.			
inv(14)/ t(14;14)(q11;q32)	Absent	Present	□ Not evaluated
del(14)(q12)	Absent	Present	□ Not evaluated
t(11;14)(q23;q11)	Absent	Present	☐ Not evaluated
t(7;14)(q35;q32.1)	Absent	Present	□ Not evaluated
t(X;14)(q35;q11)	Absent	Present	□ Not evaluated
idic(8)(p11)	Absent	Present	☐ Not evaluated
del(17p)	Absent	Present	□ Not evaluated
Other; specify:	Absent	Present	
OR			
Transcribe the complete karyotype:			



Treatment Type	П НСТ П	CT 🗌 IST	Other
Treatment Date _	//	_(YYYY/MM/DI	C)

### IMMUNOPHENOTYPING

only applicable for T-PLL

#### Immunophenotype of T-cells at diagnosis:

Note: Terminal desoxynucleotidyl transferase (TdT) must be negative.

Indicate below whether the phenotypes were absent, present or not evaluated.

CD4+	Absent	Present	☐ Not evaluated	Unknown
CD8+	Absent	Present	☐ Not evaluated	Unknown

Lymphocyte count at diagnosis: \_\_\_\_\_\_ 10<sup>9</sup> cells/L D Not evaluated D Unknown

### Was mantle cell lymphoma excluded at diagnosis?:

		No
--	--	----

Unknown

☐ Yes; **method**: ☐ FISH on t(11;14)(q23;q11)

Cyclin D1 expression

- Both
- Other

Chronic\_Leukaemias\_v2.1